Michael Dugan, MD

#Pathologist & #biotech professional, #photographer, #traveler, #author, #historian, #naturalist #politicalnewsjunkie

[Michael Dugan, MD @MikeDuganMD]

Happy to see this paper reach fruition after many delays and the 2023 demise of @Biocept. Thanks to many teammates and collaborators as we work to build a newer better version of #CNSide. #brainmets #LMD #CSF #CSFtumorcells #cancer #neurooncology
https://t.co/ptuj7i2iam

[Michael Dugan, MD @MikeDuganMD]

@BobCusack, Editor in Chief @thehill speaks at the @Pathologists House of Delegates fall meeting luncheon. #ElectionUpdates #CAP24

[Michael Dugan, MD @MikeDuganMD]

Remote #digital #pathology is the topic du jour at @Pathologists CAP 2024 House of Delegates and Annual Meeting. #CAP24 Join us!

[Michael Dugan, MD @MikeDuganMD]

Great to participate in @Pathologists 2024 House of Delegates and CAP annual meeting in Las Vegas.

[Michael Dugan, MD @MikeDuganMD]

@Biocept @Pathologists Arch Path Lab Medicine May 27, 2024

[Michael Dugan, MD @MikeDuganMD]

Happy to see this paper reach fruition after many delays and the 2023 demise of @Biocept. Thanks to many teammates and collaborators as we work to build a newer better version of #CNSide. #brainmets #LMD #CSF #CSFtumorcells #cancer #neurooncology
https://t.co/ptuj7i2iam

[NEJM @NEJM]

Neoadjuvant nivolumab plus ipilimumab results in a substantial pathological response in most patients with mismatch repair–deficient colon cancer and appears to be safe. Read the full NICHE-2 phase 2 study results: https://t.co/KCLkvTiaFy

[Paolo Tarantino @PTarantinoMD]

Key consideration: all agnostic targets approved in the past could be evaluated with NGS

The agnostic approval of T-DXd however requires HER2 IHC to be performed to identify the target.

Important to raise awareness on the need to expand HER2 testing across cancer types!

[Michael Dugan, MD @MikeDuganMD]

@PTarantinoMD Exactly. NGS is not going to identify most targets of new ADCs and IHC as currently performed has significant limitations. Much more still to do. I would like to discuss this topic more with you Paolo.

[Michael Dugan, MD @MikeDuganMD]

@nlinmd @drsarahsam Great data. I would love to discuss more with each of you. Former colleagues and I are working on a new CSF assay to address such cases. [email protected]

[Michael Dugan, MD @MikeDuganMD]

@Sara_Jiang @science_press @LizMontgomeryMD @DrWFoo @DukePathDept @TheUSCAP Congratulations!

[Michael Dugan, MD @MikeDuganMD]

@HerrPath @Pathologists Join us at CAP HOD in a few weeks for roundtable discussions on pathologist #careers in different practice settings, including #biotech.

[Amanda Herrmann MD, PhD @HerrPath]

😎🙌🏻 if you are a pathology advocate that works with students become a @Pathologists Pipeline Champion! Share ideas and successes to ensure the future of the profession we love. Love this group #PathTwitter

[Michael Dugan, MD @MikeDuganMD]

@ZhaiJim @MHebertMD Wish you and other FL colleagues well Jim.

[Michael Dugan, MD @MikeDuganMD]

@AshleySumrallMD #NSCLC shows promising intracranial response to the #NTRK inhibitor #larotrectinib. Assessing intracranial response to therapy is challenging. Our goal is improve the management of patients with CNS leptomeningeal #metastasis (LM) with #CNSide. #brainmet

[Ashley Love Sumrall, MD, FACP, FASCO @AshleySumrallMD]

Of those 3 pts w/ PR, look at depth of response below. The #brainmet from lung ca responded remarkably well. Unclear of rule of RT in these pts.

[Michael Dugan, MD @MikeDuganMD]

Finding #HER2 amplification in #breastcancer tumor cells in the CSF is critical because anti-HER2 targeted therapy provides one of the best options for physicians treating patients who have developed the life-threatening complications of LMD. https://t.co/3MYJpSLsTK

[Michael Dugan, MD @MikeDuganMD]

Don't miss today's CAP Today webinar. #csf #Cancer #tumorcells #breastcancer #metastaticbreastcancer #lungcancer #metastaticlungcancer #Melanoma #brainmetastasis @captodayonline https://t.co/UeYH9I81pq

[Michael Dugan, MD @MikeDuganMD]

Biocept and Aegea announce co-development of quantitative RT-PCR based test for SARS-COV-2/COVID-19 which discriminates strain types. #COVID19 #strains #testing #SARSCoV2 #CLIA
https://t.co/LHsFqxRcD7

[Michael Dugan, MD @MikeDuganMD]

Biocept and Protean establish collaboration to demonstrate the potential of Biocept's Target Selector EGFR assay in tissue and fluids. #liquidbiopsy #EGFR #NSCLC https://t.co/GOItWFdgpP

[University of Arizona Health Sciences @UAZHealth]

A UArizona Health Sciences-led study of prehospital care guidelines for EMS personnel treating traumatic brain injury (TBI) among children found deaths from severe #TBI can be nearly eliminated if the guidelines are implemented by first responders. https://t.co/X9DHVuyvFj